**Core tip:** Tacrolimus (FK) has surpassed cyclosporine (CYA) as the calcineurin inhibitor (CNI) of choice for the vast majority of kidney transplant (KTX) programs. Yet, CYA continues to be an important alternative for patients intolerant to FK. FK is associated with significantly lower rate of acute rejection and better graft survival compared to CYA. Individualizing immunosuppression through risk-stratified CNI choice may lead to improved outcomes across all spectra of KTX patients.

INTRODUCTION
============

Calcineurin inhibitors (CNIs) are the main immunosuppressive agents utilized in kidney transplantation\[[@B1]\]. Cyclosporine (CYA) and tacrolimus (FK) are currently the most widely used maintenance immunosuppressants for prevention of acute rejection in kidney transplant recipients. CYA-based regimen was more common in the era of 1990 until 2002, after which FK-based regimen became more commonly used in most transplant programs. In our transplant center, FK became the primary CNI of choice in 2005. FK and CYA show variable side effect profiles. Hypertension, hyperlipidemia, gum hypertrophy, and hirsutism occur more frequently with CYA use. On the other hand, a higher incidence of post-transplant diabetes mellitus is observed with FK therapy. Prolonged use of CNI may result in nephrotoxicity.

FK use is associated with less acute rejection compared to CYA, as documented in different studies\[[@B2],[@B3]\]. Mayer et al\[[@B2]\] found that among 448 renal transplant recipients who were on triple therapy (FK or CYA + Azathioprine + Prednisone), patients who were in the FK group had a significant reduction in the frequency of acute rejection at 12 mo (FK 25.9% *vs* CYA 45.7%; *P* \< 0.001). Ekberg et al\[[@B3]\] also found that at 12 mo post-transplant, the use of FK-based regimen is associated with less biopsy-proven acute rejection compared to CYA use (12.3% *vs* 25.8%, *P* \< 0.01).

FK is frequently preferred in patients with high immunologic risk (highly sensitized, ABO-incompatible organ recipients), delayed graft function, and African American race. Data regarding graft survival based on the use of FK *vs* CYA is controversial with most studies showing similar graft survival rates with the use of either agent\[[@B4]\]. Vincenti et al\[[@B5]\] showed comparable patient (79.1% *vs* 81.4%; *P* = 0.472) and graft (64.3% *vs* 61.6%; *P* = 0.558) survival between treatment arms at 5 years of follow-up among FK and CYA-treated patients. However, after accounting for patients initially on CYA who crossed over to FK, the authors found significantly reduced graft failure in the FK group\[[@B5]\]. Gonwa et al\[[@B6]\] showed that among 223 kidney transplant recipients who experienced delayed graft function, patients who used FK-based therapy had a better 3-year graft survival compared to CYA use (84.1% *vs* 49.9%, *P* = 0.02). Given these conflicting findings, this study aims to compare rates of acute rejection and graft loss among patients who receive FK and CYA.

MATERIALS AND METHODS
=====================

Patients
--------

This was a retrospective cohort study of 1835 patients who received a KTX between 1999-2012 at a single center. Patients were grouped based on the type of CNI they were prescribed: 1195 patients utilized FK-based immunosuppression whereas 640 patients were on a CYA-based regimen. All patients received an antimetabolite and prednisone in combination with CNI. The initial CYA dose was 4-5 mg/kg PO BID. Target CYA levels were 350-400 ng/mL for weeks 1-4, 250-350 ng/mL for weeks 5-12, 200-300 ng/mL within the first year post-transplant, and 100-200 ng/mL thereafter. Initial FK doses were given at 0.025-0.05 mg/kg PO BID. Target FK levels were kept between 8-12 ng/mL within the first four weeks post-transplant, then 6-10 ng/mL within the first year post-transplant, and 4-6 ng/mL subsequently. Characteristics of recipients (age, race, sex, BMI, etiology of kidney disease, history of heart disease, diabetes, hypertension, years on dialysis, panel reactive antibody, preemptive transplant, living donor transplant), and donors \[age, race, kidney donor risk index (KDRI)\] were compared between groups. Characteristics of the kidney transplant (cold ischemia time, induction agent) as well as clinical outcomes (cumulative acute rejection rate, delayed graft function, three, and five year graft survival) were also analyzed. The Banff '97 criteria were used to define the different grades of rejection. Based on center protocol, Banff 1A and 1B rejection episodes were treated with Methylprednisolone IV. Rejection episodes with Banff 2A grade or higher were treated with anti-thymocyte globulin. Subset analysis was conducted on subjects who had graft loss to retrospectively investigate the factors leading to graft loss. For patients who died, causes of death were presented as overall prevalence of infections (encompassing sepsis, bacterial, fungal, CMV, and other viral infections), malignancies (encompassing solid organ tumors, hematologic malignancies, and post-transplant lymphoproliferative disorder), and cardiovascular diseases (encompassing acute myocardial infarction and cerebrovascular accident). Cause of death classified under "other" includes accidents, unknown, or undocumented. Non-adherence was defined as documentation in the medical record by a provider that a patient was not taking their immunosuppressive regimen as prescribed. Under immunosuppression was defined as evidence of kidney transplant injury related to rejection that led or contributed to graft loss.

Statistical analysis
--------------------

The statistical review was performed by a clinician with advanced biostatistical training and experience.

Two-sided independent student's *t*-test was used to compare continuous data while the χ^2^ test was used to compare categorical data. A two-sided *P*-value of less than 0.05 was considered statistically significant.

Multivariate survival analysis, using both logistic and Cox regression, was used to assess the association between CNI choice and acute rejection (logistic), graft survival (Cox), and patient mortality (Cox), while controlling for additional transplant variables known to influence outcomes or those that differed across CNI choice. In a subset analysis of patients who had graft loss, causes of graft loss, and causes of death were compared between the two groups using standard univariate comparative statistics. All analyses were conducted using SPSS version 21.0 (IBM Corp, Armonk, NY).

RESULTS
=======

Patient characteristics
-----------------------

Table [1](#T1){ref-type="table"} displays demographic characteristics of the two groups. Mean recipient age, race, BMI, etiology of kidney disease, comorbidities, and dialysis vintage, were similar between the two groups. Patients on FK had higher PRA compared to patients on CYA group (17% *vs* 5%, *P* \< 0.01). Rates of living donor transplants were similar between the two groups. Among patients who received a deceased donor transplant, KDRI was higher in those who received FK. More patients in the FK group received induction agent with depleting antibodies (46% *vs* 11%, *P* \< 0.01).

###### 

Characteristics of patients in tacrolimus and cyclosporine group *n* (%)

  **Parameter**                **Cyclosporine *n* = 640**   **Tacrolimus *n* = 1195**   ***P*-value**
  ---------------------------- ---------------------------- --------------------------- ---------------
  Mean recipient age (yr)      49 ± 12                      50 ± 13                     0.059
  Race                                                                                  0.96
  Non-African American         281 (44)                     526 (44)                    
  African-American             359 (56)                     669 (56)                    
  Sex                                                                                   0.78
  Male                         371 (58)                     693 (58)                    
  Female                       269 (42)                     502 (42)                    
  BMI                          26 ± 7                       28 ± 5                      0.462
  Etiology of kidney disease                                                            
  DM                           172 (26.9)                   375 (31.4)                  0.044
  HTN                          317 (49.5)                   559 (46.8)                  0.26
  FSGS                         36 (5.6)                     78 (7.3)                    0.177
  IgA nephropathy              24 (3.8)                     34 (2.8)                    0.291
  Polycystic kidney            63 (9.8)                     89 (7.4)                    0.076
  History of DM                186 (29)                     394 (33)                    0.092
  History of HTN               595 (93)                     1135 (95)                   0.122
  History of heart disease     134 (21)                     227 (19)                    0.38
  Years on dialysis            3 ± 2.4                      3 ± 2.9                     0.01
  PRA                          5%                           17%                         \< 0.010
  Preemptive transplant        122 (19)                     239 (20)                    0.49
  Living donor transplant      122 (19)                     179 (15)                    0.27
  CIT (h)                      13 ± 9                       16 ± 9                      0.621
  Mean donor age (yr)          31 ± 18                      36 ± 16                     \< 0.010
  KDRI                         0.9 ± 0.6                    1.3 ± 0.4                   \< 0.010
  African-American donor       122 (19)                     203 (17)                    0.27
  Induction therapy                                                                     \< 0.010
  Cytolytic agents             70 (11)                      550 (46)                    
  IL-2 receptor antagonist     570 (89)                     645 (54)                    

DM: Diabetes mellitus; HTN: Hypertension; FSGS: Focal segmental glomerulosclerosis; PRA: Panel reactive antibody; CIT: Cold ischemia time; KDRI: Kidney donor risk index.

Clinical outcomes
-----------------

Patients in the FK group had better clinical outcomes in terms of delayed graft function (DGF) rate (15% *vs* 18%, *P* = 0.049), cumulative biopsy proven acute rejection rates for Banff 1A and higher, as well as antibody-mediated rejection (14% *vs* 24%, *P* \< 0.01), three year graft survival (88% *vs* 79%, *P* \< 0.010), and five year graft survival (84% *vs* 70%, *P* \< 0.01) (Table [2](#T2){ref-type="table"}). FK was a strong predictor of lower acute rejection rates. After multivariate analysis, which accounted for recipient immunologic risks (age, gender, re-transplant, PRA, HLA mismatches, cold ischemic time, induction), donor characteristics (deceased status, ECD, age, race) and delayed graft function, FK continued to be strongly associated with lower acute rejection rates, as compared to CYA (OR = 0.60, 95%CI: 0.45-0.79; *P* \< 0.001) (Table [3](#T3){ref-type="table"}). Further analysis showed that even after controlling for all other variables, including delayed graft function and acute rejection, FK remained a strong and statistically significant predictor of graft survival (OR = 0.740, 95%CI: 0.58-0.94; *P* = 0.012) (Table [4](#T4){ref-type="table"}) (Figure [1](#F1){ref-type="fig"}).
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###### 

Clinical outcomes

  **Parameter**                             **Tacrolimus *n* = 1195**   **Cyclosporine *n* = 640**   ***P*-value**
  ----------------------------------------- --------------------------- ---------------------------- ---------------
  Mean glomerular filtration rate           56 ± 19                     46 ± 17                      0.09
  Delayed graft function *n* (%)            179 (15)                    115 (18)                     0.049
  Acute rejection (biopsy proven) *n* (%)   167 (14)                    154 (24)                     \< 0.010
  Three years graft survival                88%                         79%                          \< 0.010
  Five years graft survival                 84%                         70%                          \< 0.010

###### 

Multivariate analysis of factors associated with acute rejection

  **Variable**          **Hazard ratio**   **95%CI**   ***P*-value**
  --------------------- ------------------ ----------- ---------------
  CNI tacrolimus        0.6                0.45-0.79   \< 0.001
  Retransplant          1.43               0.91-2.24   0.123
  PRA                   1                  0.99-1.00   0.529
  Cytolytic induction   0.5                0.36-0.69   \< 0.001

CNI: Calcineurin inhibitor; PRA: Panel reactive antibody.

###### 

Multivariate analysis of factors associated with graft loss

  **Variable**             **Hazard ratio**   **95%CI**   ***P*-value**
  ------------------------ ------------------ ----------- ---------------
  CNI tacrolimus           0.74               0.58-0.94   0.012
  History of DM            1.41               1.13-1.76   0.002
  History of HTN           0.56               0.34-0.94   0.029
  Delayed graft function   2.1                1.66-2.66   \< 0.001
  Acute rejection          1.59               1.26-2.01   \< 0.001

CNI: Calcineurin inhibitor; DM: Diabetes mellitus; HTN: Hypertension.

Graft loss
----------

During the study period, there were 106 patients in the FK group and 123 in the CYA group who had graft loss. Death with a functioning graft was the cause of graft loss in the majority of these patients. The leading causes of death among the patients include cardiovascular disease, infections, and malignancies (Table [5](#T5){ref-type="table"}). The contribution of non-adherence and underimmunosuppression in patients who had graft loss was not significantly different between the FK and CYA groups.

###### 

Graft loss *n* (%)

  **Parameter**                         **Tacrolimus *n* = 106**   **Cyclosporine *n* = 123**   ***P*-value**
  ------------------------------------- -------------------------- ---------------------------- ---------------
  Death with functioning graft          61 (58)                    66 (54)                      0.55
  Cause of death                                                                                0.85
  Cardiovascular disease                19 (18)                    19 (15)                      
  Infections                            10 (9)                     9 (7)                        
  Malignancy                            10 (9)                     9 (7)                        
  Others                                33 (31)                    41 (33)                      
  Causes of graft loss                                                                          0.44
  Chronic allograft nephropathy         18 (17)                    29 (24)                      
  Acute rejection                       14 (13)                    11 (9)                       
  Acute on chronic rejection            8 (8)                      13 (11)                      
  Recurrent disease                     1 (1)                      1 (1)                        
  Death                                 63 (59)                    68 (55)                      
  Component of non- adherence           15 (14)                    20 (16)                      0.65
  Component of underimmunosuppression   21 (20)                    25 (20)                      0.92

DISCUSSION
==========

The utilization of potent immunosuppressive medications such as CYA and FK has led to progressive improvement in renal allograft survival. Two large studies on kidney transplant recipients showed that the incidence of acute rejection is much lower with FK-based immunosuppression compared to CYA-based regimen\[[@B2],[@B3]\]. Our study demonstrated similar findings of lower acute rejection rates in patients using FK compared to those on CYA. Acute rejection rate was significantly lower in the FK group despite the relatively higher degree of sensitization, as evidenced by higher PRA, in this group. Multivariate analysis showed that FK was a strong predictor for lower acute rejection rates while controlling for recipient, donor, and transplant characteristics.

The shortage of deceased donor kidneys and the growing number of patients on the waiting list has driven the increased utilization of organs with relatively marginal donor characteristics. Donor factors affect initial graft function and survival\[[@B7]\]. Donor factors that may influence graft survival include age, gender, hypertension, and cardiovascular disease\[[@B8]\]. The KDRI is a comprehensive metric that was recently developed to assess the relative risk of graft failure associated with various combinations of donor characteristics. Kidneys with the highest KDRI quintile are associated with lower graft survival\[[@B9]\]. Although many trials have shown similar graft survival outcomes with FK when compared with CYA-based regimen\[[@B4]\], some studies showed better survival and outcomes with FK-based immunosuppression\[[@B6]\]. Our study showed that although patients in the FK group received kidneys from more marginal donors (higher KDRI), the three year and five year graft survival was still more superior in this group compared to the CYA group (Figure [1](#F1){ref-type="fig"}).

The risk of infections after kidney transplant depends on the net state of immunosuppression. As FK was shown to be associated with less acute rejection compared to CYA\[[@B10]\], it may concurrently cause more intense immunosuppressive effects compared to CYA. Thus, risk of infections after kidney transplant may be higher with FK compared to CYA. This may be exemplified by the higher incidence of polyomavirus (BK) viremia in patients on FK-based regimen compared to CYA\[[@B11]\]. Progression of BK viremia may lead to BK nephropathy, which can then eventually cause premature renal allograft failure\[[@B11]\]. However, in our subjects who had graft loss, we did not observe a significant difference in the prevalence of infections (including BK) in the FK and CYA groups.

The use of maintenance immunosuppressive medications among transplant recipients increases the long-term risk of malignancy, compared with that of the general population. The overall level of immunosuppression appears to be the principal factor that increases the risk of post-transplant malignancy. Both FK and CYA are associated with an increased risk of malignancy following kidney transplant\[[@B12],[@B13]\]. No direct comparison between these two agents has been reported regarding the incidence of malignancy following kidney transplant. However, FK was found to have higher incidence of *de novo* malignancy after liver transplant compared to CYA\[[@B14]\]. In our study, we did not find a significant difference in the prevalence of malignancies between the two groups.

Cardiovascular disease is a leading cause of mortality among kidney transplant recipients. Death from cardiovascular disease is the most common cause of renal allograft loss\[[@B15]\]. CNIs potentially contribute to increased risk of cardiovascular events indirectly by the development of new-onset diabetes mellitus, hypertension, and hyperlipidemia. Clinical trials have shown a higher incidence of post-transplant diabetes mellitus with FK. However, the risk of hypertension and hyperlipidemia is slightly higher with CYA than FK. No direct comparison has been done between FK and CYA regarding the incidence of cardiovascular disease. In our study, we found that FK was associated with a slightly higher prevalence of cardiovascular disease compared to CYA, although the difference was not statistically significant.

In conclusion, FK is associated with lower prevalence of acute rejection compared to CYA. It confers better three and five year graft survival even with the use of organs with marginal deceased donor characteristics. An individualized approach to the choice of CNI needs to be employed in order to achieve the best possible outcome while minimizing adverse effects. The use of either FK or CYA should be individualized according to the patient's comorbid conditions and immunological risk.

COMMENTS
========

Background
----------

Calcineurin inhibitors (CNIs) \[cyclosporine (CYA) and tacrolimus (FK)\] are currently the most widely used maintenance immunosuppressants for prevention of acute rejection following kidney transplantation. However, data on the impact of these CNIs on acute rejection rate and graft survival have remained equivocal.

Research frontiers
------------------

The choice of immunosuppressive regimen that will achieve the best renal allograft outcomes remains an important focus in the care of kidney transplant recipients.

Innovations and breakthroughs
-----------------------------

The data showed lower acute rejection rates and better graft survival in patients on FK compared to those on CYA.

Applications
------------

The use of either FK or CYA should be individualized based on patient's comorbidities and immunological risk.

Terminology
-----------

FK: Tacrolimus; CYA: Cyclosporine; CNI: Calcineurin inhibitor; DGF: Delayed graft function; DM: Diabetes mellitus; HTN: Hypertension; FSGS: Focal segmental glomerulosclerosis; PRA: Panel reactive antibody; CIT: Cold ischemia time; KDRI: Kidney donor risk index; GFR: Glomerular filtration rate.

Peer-review
-----------

The authors are presenting their experience in the use of CNIs in the immunosuppression post renal transplantation.

Institutional review board statement: This study was reviewed and approved by the Medical University of South Carolina Institutional Review Board (IRB).

Informed consent statement: Retrospective analysis was performed on deidentified clinical data. After review, the IRB waived the requirements for individual informed consent because the study was considered minimal risk and strict safeguards are in place to ensure confidentiality of those included in the analysis.

Conflict-of-interest statement: The authors have no conflict of interest to declare.

Data sharing statement: No additional data are available.

Manuscript source: Invited manuscript

Specialty type: Transplantation

Country of origin: United States

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

Peer-review started: April 28, 2016

First decision: July 5, 2016

Article in press: September 23, 2016

P- Reviewer: Donkov II, Gheith O, Sheashaa HA S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ

[^1]: Author contributions: Kamel M contributed to data collection, manuscript writing, and manuscript revision; Kadian M contributed to data collection and manuscript writing; Srinivas T contributed to study design and manuscript revision; Taber D contributed to study design, data analysis, and manuscript revision; Posadas Salas MA contributed to study design, data collection, manuscript writing, and manuscript revision.

    Correspondence to: Maria Aurora Posadas Salas, MD, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC 29425, United States. <posadas@musc.edu>

    Telephone: +1-843-7922123 Fax: +1-843-7928399
